57 results about "Cardiolipin" patented technology

Negatively charged phospholipids, as well as compositions including negatively charged phospholipids and possibly carotenoids and / or antioxidants, for treating the eye are disclosed. In a preferred embodiment, a composition comprising at least one negatively charged phospholipid except cardiolipin is used to treat age-related macular degeneration. Methods for producing the negatively charged phospholipids, as well as methods for producing the compositions including negatively charged phospholipids and possibly carotenoids and / or antioxidants for treating age-related macular degeneration, are also disclosed.

The invention provides new synthetic routes for cardiolipin with different fatty acids and / or alkyl chains with varying chain length and also with or without unsaturation. The reaction schemes can be used to generate new forms of cardiolipin, including cardiolipin variants. The cardiolipin prepared by the present methods can conveniently be incorporated into liposomes and other lipid formulations that can also include active agents such as hydrophobic or hydrophilic drugs. Such formulations can be used to treat diseases or in diagnostic and / or analytical assays. Liposomes also can include ligands, e.g., for targeting them to a cell type or specific tissue.

The present invention is for novel compositions and methods for treating diseases caused by cellular proliferation, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include SN-38 lipid complexes in which the complexes can contain any of a variety of neutral or charged lipids and, desirably, cardiolipin. The compositions are capable of efficiently incorporating SN-38 into complexes and are capable of solubilizing relatively high concentrations of SN-38.

The present application describes compositions, methods and devices for detecting anti-lipid antibodies and diagnosing diseases such as syphilis. In particular, methods for immobilizing lipid antigens (including cardiolipin, lecithin, and cholesterol) on solid supports (eg, nitrocellulose membranes) are described. The ability to immobilize lipid antigens on membranes fulfills a long known need for a membrane-based assay for the detection of anti-lipid antibodies. An immunoassay device for simultaneous treponema pallidum and non-treponemal testing is also described.

This invention pertains to liposomal formulations of mitoxantrone and methods for their manufacture and use. The compositions of the present invention include liposomal formulations of mitoxantrone in which the liposome contains any of a variety of neutral or charged liposome-forming materials in addition to a compound that is thought to bind mitoxantrone, such as cardiolipin. The liposomal compositions can be used advantageously in conjunction with secondary therapeutic agents other than mitoxantrone, including antineoplastic, antifungal, antibiotic among other active agents. Methods are provided in which a therapeutically effective amount of the formulation is administered to a mammal, such as a human.

The invention provides new synthetic routes for cardiolipin with different fatty acids and / or alkyl chains with varying chain length and also with or without unsaturation, particularly a short-chain cardiolipin. The methods comprise reacting a 1,2-O-sn-diacyl / 1,2-O-sn-dialkyl glycerol or a 2-O-protected glycerol, with a phosphoramidite reagent or a phosphate triester to produce a protected cardiolipin, which is deprotected to prepare the short chain cardiolipin. The reaction schemes can be used to generate new variants of cardiolipin. The cardiolipin prepared by the present methods can be incorporated into liposomes, which can also include active agents such as hydrophobic or hydrophilic drugs. Such liposomes can be used to treat diseases or in diagnostic and / or analytical assays. Liposomes can also include ligands for targeting a particular cell type or specific tissue.

The present invention is for novel compositions and methods for treating cancer, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include liposome entrapped irinotecan in which the liposome can contain any of a variety of neutral or charged liposome-forming compounds and cardiolipin. The liposomes of the present invention can be either multilamellar vesicles and unilamellar vesicles, as desired.

SN38, camptothecin derivatives are poorly water soluble, highly lipophilic camptothecin derivatives and are very active against a variety of human cancers. Because of their very poor water solubility, SN38 has not been used to treat human patients with cancer due to the inability to administer sufficient quantities of dissolved in a pharmaceutical formulation. This invention overcomes these limitations by teaching novel pharmaceutically acceptable SN38 liposome complex formulation for the direct administration of the formulation to human patients with cancer. The claimed invention also describes the methods to prepare liposomal SN38 complexes and antitumor compositions of liposomal SN38 complexes to allow the administration in sufficient amounts to treat various types of cancer and as antiviral agents. This invention is also directed to injectable sterile solutions, antitumor compositions, liposomes. The present invention is for novel compositions and methods for treating diseases caused by cellular proliferation, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include SN38 lipid complexes in which the complexes can contain any of a variety of neutral or charged lipids and, desirably, cardiolipin. The compositions are capable of efficiently incorporating SN38 into complexes and are capable of solubilizing relatively high concentrations of SN38.

A method of treating a living mammal having diabetic cardiomyopathy comprises administering an effective amount of an inhibitor to the mammal performing a shotgun lipidomics analysis on the mammal and determining that the treatment was successful when and if serum or tissue biopsy cardiolipin levels are increased and / or lysocardiolipin levels are decreased.

This invention pertains to liposomal formulations of mitoxantrone and methods for their manufacture and use. The compositions of the present invention include liposomal formulations of mitoxantrone in which the liposome contains any of a variety of neutral or charged liposome-forming materials in addition to a compound that is thought to bind mitoxantrone, such as cardiolipin. The liposomal compositions can be used advantageously in conjunction with secondary therapeutic agents other than mitoxantrone, including antineoplastic, antifungal, antibiotic among other active agents. Methods are provided in which a therapeutically effective amount of the formulation is administered to a mammal, such as a human.

Compositions comprising a water soluble spinach extract, compositions comprising a water soluble spinach extract, a liposome, a cardiolipin, and at least one antioxidant, compositions comprising a water soluble spinach extract, an extract of Arabidopsis thaliana or of the mustard (Brassica) plant, a liposome, a cardiolipin, and at least one antioxidant, processes for obtaining such compositions, and methods of using such compositions to repair damage to nuclear DNA, mitochondrial DNA, or both, prevent or decrease damage to such DNA from, for example, reactive oxygen species or 8-hydroxydeoxyguanosine and / or to repair or prevent mitochondrial damage and loss of membrane fluidity are disclosed. Compositions of the present invention may be topically administered, orally administered or parenterally, such as administration by injection. When topically administered, additives such as penetration enhancers, fragrances, preservatives, moisturizers and cosmetic adjuvants may be included in compositions of the present invention.

The present subject matter relates to a one-step method of detecting and quantifying cardiolipin in a sample using a positively charged AIE luminogen by introducing the AIE luminogen to a solution containing the sample and measuring fluorescence intensity of the solution; a method of quantifying isolated mitochondria using a positively charged AIE luminogen by staining a sample containing isolated mitochondria with the AIE luminogen and measuring the fluorescence intensity; and a method of quantifying isolated mitochondria using a positively charged AIE luminogen by introducing the AIE luminogen to a sample containing isolated mitochondria, wherein the AIE luminogen stains the isolated mitochondria and identifying the stained isolated mitochondria under microscope. With improved sensitivity and excellent selectivity to CL over other major mitochondrial membrane lipids, an aggregation-induced emission-active fluorogen, TTAPE-Me, may serve as a valuable fluorescent sensor for CL detection and quantification and the quantification of isolated mitochondria.

It is intended to provide a vector for delivering a target substance into a nucleus or a cell. This object is achieved by providing a vector for delivering a target substance into a nucleus or a cell which comprises a lipid membrane structure having a lipid membrane containing an anionic lipid such as phosphatidic acid, cardiolipin, etc.

The present invention discloses a dedicated multi-index protein chip for female infertility detection and a kit thereof. The protein chip consists of a substrate, protein detection indexes arranged on the substrate in an array mode and a contrast coating for the detection indexes. The protein detection indexes cover ovary antigen (OAg), endometrium antigen (EAg), sperm antigen (SAg), zona pellucida antigen (ZAg), human chorionic gonadotropin antigen (HCG), trophoblast antigen (TAg) and cardiolipin antigen (CAg). The present invention overcomes the defects of the existing autoimmunological detection products on market, such as single detection function, lagged detection indexes and no integration. Besides the indexes of the product (patent application No: 200510102466.3), the protein chip also has the ACA index. The density of all indexes can be quantitatively detected, and the cross reaction of all indexes is eliminated. The present invention not only has high specificity and high sensitivity, but also has high accuracy and precision.

Disclosed herein is a composition comprising a liposome, a cardiolipin, and at least one antioxidant, wherein the composition is useful for improving, maintaining, or restoring a mitochondrial membrane and / or mitochondrial function. In one example, the liposome is primarily composed of phosphatidylcholine, the cardiolipin is tetraoleoyl-cardiolipin, and the at least one antioxidant is methylgentisate, l-carnosine, or both. The composition may be topically administered, orally administered, or parenterally administered, for example administered by injection. If topically administered, the composition may be administered for example, as a cream, lotion, gel, paste, spray, tonic, or other suitable form and may contain various additives, for example, one or more of an emollient, a humectant, a penetration enhancer, a vitamin, a fragrance, a pigment, and a moisturizer.

The invention discloses an application of a novel liposome-entrapped mitoxantrone combined chemotherapeutic drug in antineoplastic treatment. According to the invention, a new liposome-entrapped mitoxantrone preparation containing components such as cardiolipin is prepared internationally, and is used for being combined with other clinical routine first-line chemotherapeutics for antineoplastic treatment. The invention expounds the preparation method and symptom research of the novel liposome preparation, the preparation has the characteristics of high entrapment rate, uniform particle size distribution, good stability, prolongation of chemotherapeutics half life, and reduction of toxic and side effect; compared with other treatment methods, in breast cancer and leukemia tumor animal models, antineoplastic curative effect of the new liposome-entrapped mitoxantrone preparation and other chemotherapeutics is more obvious.

The present invention is for novel compositions and methods for treating cancer, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include liposome entrapped irinotecan in which the liposome can contain any of a variety of neutral or charged liposome-forming compounds and cardiolipin. The liposomes of the present invention can be either multilamellar vesicles and unilamellar vesicles, as desired.

Phospholipid scramblase 3 (PLS3) is a newly recognized member of a family of proteins responsible for phospholipid translocation between two lipid compartments. A novel isoform of PLS3 is identified and characterized herein. The function of PLS3 in mitochondria was disrupted, yielding an inactive mutant PLS3(F258V). Cells transfected with PLS3(F258V) exhibited reduced proliferative capacity that was unaffected by the presence of Na3N. PLS3(F258V)-expressing cells exhibit abnormal mitochondrial metabolism and structure and were associated with decreased sensitivity to UV- and tBid-induced apoptosis, and diminished translocation of cardiolipin to the outer mitochondrial membrane. Cells transfected with wild-type PLS3 displayed increased sensitivity to apoptosis and enhanced cardiolipin translocation. These studies identify PLS3 as a regulator of mitochondrial structure and respiration, and cardiolipin transport in apoptosis.

An antigen composition and method for the detection of antibodies to Treponema pallidum and the diagnosis of syphilis are described. The antigen composition contains synthetic cardiolipin and synthetic lecithin. The antigen composition may additionally contain cholesterol and an alcohol. The antigen composition is useful as an immunoreagent in immunoassays for the detection of antibodies associated with T. pallidum infection. The methods are sensitive and specific for T. pallidum infection.

Low levels of antibodies reactive with oxidised Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunisation and therapy of these diseases and conditions are provided.

The present invention is for novel compositions and methods for treating cancer, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include liposome entrapped vinorelbine in which the liposome can contain any of a variety of neutral or charged liposome-forming compounds and cardiolipin. The liposomes of the present invention can be either multilamellar vesicles or unilamellar vesicles, as desired.

An antigen composition and method for the detection of antibodies to Treponema pallidum and the diagnosis of syphilis are described. The antigen composition contains synthetic cardiolipin and synthetic lecithin. The antigen composition may additionally contain cholesterol and an alcohol. The antigen composition is useful as an immunoreagent in immunoassays for the detection of antibodies associated with T. pallidum infection. The methods are sensitive and specific for T. pallidum infection.

The invention provides novel synthetic methodologies for preparing cardiolipin, migrated caridiolipin (1,2-positional isomer of cardiolipin) and their analogues having varying fatty acids and / or alkyl chains with varying length and degrees of saturation / unsaturation. The method comprises (a) reacting an optically pure 1,2-O-dialkyl-sn-glycerol or 1,2-O-dialkyl-sn-glycerol with one or more phosphoramidite reagent(s), wherein a phosphite triester is produced; (b) coupling the product of (a) with glycerol, wherein a protected cardiolipin is produced; and (c) deprotecting the protected cardiolipin, such that cardiolipin is prepared. The cardiolipins and analogues thereof, prepared by the present methods, can be incorporated into liposomes, which can also include active agents such as hydrophobic or hydrophilic drugs, antisense nucleotides or diagnostic agents. Such liposomes can be used to treat diseases or can be used in diagnostic and / or analytical assays.

The invention provides a western blot kit for cardiolipin and specific IgM antibodies of syphilis and preparation thereof, relating to a kit. The kit is provided with a carrier plate, a cellulose nitrate membrane, a detection line of the specific IgM antibodies and cardiolipin IgM antibodies of the syphilis and a control line, wherein the detection line and the control line are arranged on the cellulose nitrate membrane in sequence; specific recombinant antigens and cardiolipin antigens of the syphilis are coated at the detection line of the specific IgM antibodies of the syphilis, and human IgM antibodies are coated at the control line; and horse radish peroxidase is marked on anti-human mu-chain antibodies. The preparation comprises the following steps: preparing the specific recombinant antigens of the syphilis, then preparing the cardiolipin antigens, carrying out sample application on the cellulose nitrate membrane, and preparing mu-chain monoclonal antibodies of anti-human IgM specific segments; and marking the horse radish peroxidase on the anti-human IgM specific segments mu-chain monoclonal antibodies, and then preparing the western blot kit. The kit provided by the invention can be used for detection of the specific IgM antibodies and cardiolipin antigens of the syphilis in specimens such as whole blood, blood serum, blood plasma, cerebrospinal fluid and the like.

The present invention provides a new synthesis route for cardiolipin, especially short-chain cardiolipin, having different fatty acids and / or alkyl chains of different chain lengths, with or without unsaturation. The method comprises: reacting 1,2-O-sn-diacyl / 1,2-O-sn-dialkylglycerol or 2-O-protected glycerol with phosphoramidite reagent or phosphotriester to generate protected Cardiolipin, which is deprotected to prepare short-chain cardiolipin. This reaction scheme can be used to generate new variants of cardiolipin. Cardiolipin prepared by this method may be contained in liposomes, which may also contain active agents, such as hydrophobic or hydrophilic drugs. Such liposomes may be used in the treatment of diseases or in diagnostic and / or analytical assays. Liposomes can also contain ligands for targeting to specific cell types or specific tissues.

The invention provides synthetic methods for PEGylated cardiolipins with varying linkers. The methods can be employed to prepare PEGylated cardiolipin with different fatty acid and / or alkyl chain length with or without unsaturation. The PEGylated cardiolipin, prepared by the present methods, can be incorporated into liposomes that can also include active agents such as hydrophilic or hydrophobic drugs for the treatment of human and animal diseases. In addition, the PEGylated cardiolipin can be incorporated into liposomes that include compounds for therapeutic and diagnostic imaging. The use of such liposomes with PEGylated cardiolipin prolongs the period of liposomal circulation without disrupting the lipid bilayer.

The invention relate to a high-density sialic acid modified ibrutinib (IBR) nanocomposite and a preparation method thereof. The sialic acid modified IBR nanocomposites comprises IBR, phospholipid anda sialic acid derivative, wherein the molar ratio of IBR to phospholipid is 1:0.5 to 1:5, and the molar ratio of the sialic acid derivative to phospholipid is 1:19 to 1:1. The phospholipid is one or more of phosphatidylglycerol, phosphatidic acid, phosphatidylserine, phosphatidylinositol and cardiolipin. The nanocomposite can obviously improve the drug dissolution performance, provides an injectable product for reducing the daily dose of drugs, and can be used for clinical critical patients to solve the problem that the patients cannot take drugs orally. Based on the theory of ''immunopharmaceuticals'', the sialic acid is used to modify the composite, accumulation of the preparation in tumor site and the inhibitory effect on tumor microenvironment stromal cells are increased, so that the tumor therapeutic spectrum of IBR is expanded, and the drug efficacy is improved.

The present invention relates to a method for inhibiting a disease response in a subject comprising contacting dead or dying cells exposing an antigen selected from the group consisting of a phosphorylcholine (PC) determinant, a phosphatidyl serine (PS) determinant, a MDA determinant, and cardiolipin in the subject, with an antibody or recombinant protein that recognizes and binds the antigen that is exposed on the dead or dying cells, thereby inhibiting the pathologic response in the subject.

The invention discloses a recombinant plasmid of a GSDMD-N (gasdmermin D-N) gene, an expression method in mammary gland and an application, and belongs to the field of genetic engineering. An expression recombinant plasmid of the GSDMD-N gene is constructed and enabled to be specifically expressed in breast tissue and breast cells, so that mastitis caused by staphylococcus aureus infection is prevented and treated. GSDMD-N protein is a polypeptide compound found in recent years, which can specifically recognize biofilm component cardiolipin of bacteria and can be combined with cardiolipin to form a plurality of honeycomb-shaped pores, so that bacteria are disintegrated and die. According to the technology, the exogenous gene GSDMD-N is efficiently expressed in animal mammary glands througha specific promoter WAP (whey acidic protein) of breast tissue by a mammary bioreactor, staphylococcus aureus causing cow mastitis is killed, and accordingly, the cow mastitis caused by staphylococcus aureus infection is prevented and treated. The recombinant plasmid and the recombinant attenuated salmonella have the advantages of being efficient, safe, low in cost and the like, provide a a new approach for prevention and control of the cow mastitis caused by staphylococcus aureus infection, and have good application prospect.